Description
About Bonspri Injection
Bonspri Injection contains ofatumumab, a monoclonal antibody supplied in a pre-filled syringe for subcutaneous injection. The first dose is normally given under supervision, after which it may be self-administered at home if your doctor is satisfied you can do so safely.
How it works
Ofatumumab attaches to CD20, a protein found on the surface of B cells. B cells are part of the immune system and play a role in the nerve damage seen in multiple sclerosis. By binding to them, ofatumumab causes those cells to be cleared from the circulation, reducing the immune attack on the protective coating around nerves.
What it is used for
Ofatumumab is used in the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Important safety information
Because it reduces B cells, ofatumumab increases the risk of infection; report fever, persistent cough or other signs of infection to your doctor. Screening for hepatitis B is carried out before treatment, as the virus can reactivate. Injection-related reactions are common with the first doses. Live vaccines should not be given during treatment, and vaccinations should be brought up to date beforehand. Tell your doctor if you are pregnant, planning a pregnancy or breastfeeding, and about any current infection or immune condition.
This is a prescription-only medicine. It should be used only under the supervision of a qualified healthcare professional, who will decide whether it is suitable for you and at what dose.


Reviews
There are no reviews yet.